Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies.

ABSTRACT: Serology tests can identify previous infections and facilitate estimation of the number of total infections. However, immunoglobulins targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported to wane below the detectable level of serological assays. We estimate the cumulative incidence of SARS-CoV-2 infection from serology studies, accounting for expected levels of antibody acquisition (seroconversion) and waning (seroreversion), and apply this framework using data from New York City (NYC) and Connecticut. We estimated time from seroconversion to seroreversion and infection fatality ratio (IFR) using mortality data from March-October 2020 and population-level cross-sectional seroprevalence data from April-August 2020 in NYC and Connecticut. We then estimated

SUBMITTER: Shioda K 

PROVIDER: S-EPMC7685353 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature